OPKO Health (NASDAQ:OPK) Downgraded to "Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded OPKO Health (NASDAQ:OPK) from a "hold" to a "sell" and other firms have cut targets (Barrington to $1.50), though the consensus rating remains "Hold" with a $2.03 target.
• OPKO's most recent quarter beat estimates (EPS -$0.04 vs. -$0.07 expected; revenue $148.5M vs. $139.8M expected) but revenue is down 19.1% year‑over‑year and the company reports negative net margin (-37.19%) and ROE (-17.42%), with analysts forecasting -0.25 EPS for the year.
• The stock trades around $1.18 (12‑month range $1.11–$1.95) with a market cap of about $896M and a negative PE, underscoring continued downside risk for investors.

OPKO Health (NASDAQ:OPK - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday.

OPK has been the subject of several other reports. Barrington Research reduced their price objective on OPKO Health from $2.25 to $1.50 and set an "outperform" rating for the company in a research report on Monday, March 2nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of OPKO Health in a research note on Thursday, January 22nd. Finally, JPMorgan Chase & Co. started coverage on shares of OPKO Health in a report on Thursday, November 20th. They issued a "neutral" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $2.03.

OPKO Health Price Performance

NASDAQ OPK opened at $1.18 on Friday. OPKO Health has a twelve month low of $1.11 and a twelve month high of $1.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.32 and a current ratio of 3.97. The stock has a market capitalization of $895.70 million, a PE ratio of -3.93 and a beta of 1.50. The stock has a 50-day simple moving average of $1.26 and a 200 day simple moving average of $1.35.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. The firm had revenue of $148.50 million for the quarter, compared to analyst estimates of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The company's revenue was down 19.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.01 EPS. Research analysts anticipate that OPKO Health will post -0.25 EPS for the current year.

Institutional Investors Weigh In On OPKO Health

Large investors have recently modified their holdings of the stock. Caprock Group LLC acquired a new position in shares of OPKO Health in the 3rd quarter worth approximately $26,000. Zacks Investment Management acquired a new stake in OPKO Health in the 4th quarter valued at $27,000. StoneX Group Inc. acquired a new stake in OPKO Health in the 4th quarter valued at $27,000. Swiss Life Asset Management Ltd bought a new stake in OPKO Health in the third quarter valued at $30,000. Finally, Savant Capital LLC acquired a new position in OPKO Health during the third quarter worth $33,000. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc NASDAQ: OPK is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.